In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Opts for Access Over Exclusivity in Antibodies

Executive Summary

For its biggest antibody deal to date, Pfizer choose Medarex, which insists on non-exclusive agreements, leaving the biotech free to work with other partners on any given target. In doing so, Pfizer reckoned that the potential for competition with respect to a particular target was outweighed by the greater access to targets which Medarex's deal model provides.
Advertisement

Related Content

Finding a Way Out of Pharma's Dealmaking Dilemma
Finding a Way Out of Pharma's Dealmaking Dilemma
Amgen/Abgenix: All About a Drug
Big Pharma's Large Molecule Challenge
Big Pharma's Large Molecule Challenge
Protein Production Start-Ups
In Cancer, the Antibody Beat Goes On
In Cancer, the Antibody Beat Goes On

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel